Search for: "PAR PHARMACEUTICALS"
Results 201 - 220
of 303
Sort by Relevance
|
Sort by Date
16 Nov 2010, 8:58 am
The following was sent in by Gene Quinn, of IPWatchdog and Practice Center Contributor. [read post]
15 Nov 2010, 10:25 am
Senator Birch Bayh On October 12, 2010, I had the honor of interviewing retired United States Senator Birch Bayh at his office at Venable LLP. [read post]
17 Oct 2010, 9:55 am
Her expertise is working with employers to reduce workers compensation costs, and her clients include airlines, healthcare, printing/publishing, pharmaceuticals, retail, hospitality and manufacturing. [read post]
28 Sep 2010, 3:14 pm
Par Pharmaceutical, Inc; Schering-Plough Healthcare Products, Inc. et al. v. [read post]
26 Sep 2010, 8:41 pm
Par Pharmaceutical Companies, Inc. et al. 1:10-cv-07310; filed September 22, 2010 in the Southern District of New York • Plaintiff: Biovail Laboratories International SRL • Defendants: Par Pharmaceutical Companies, Inc.; Par Pharmaceuticals, Inc. [read post]
23 Sep 2010, 9:20 pm
By James DeGiulio -- Sham Litigation Claims against Par and Paddock Continue in AndroGel Litigation Par Pharmaceutical and Paddock Laboratories received clarification that their agreements with Solvay not to release competing versions of the testosterone supplement AndroGel are still subject to sham litigation claims brought by direct purchasers. [read post]
27 Aug 2010, 2:41 pm
Ortho Pharmaceutical Corp., 209 Cal. [read post]
18 Aug 2010, 12:19 am
Par Pharmaceutical, Inc. et al. [read post]
27 Jul 2010, 7:18 pm
Efforts are under way in the courts and congress to reign in patent settlement agreements under which the brand-name drug firm pays its potential generic competitor to abandon a patent challenge and delay entering the market.The agency is currently pursuing two major pay-for-delay cases: one against Solvay Pharmaceuticals (owned by Abbott Laboratories) and generic manufacturers (Watson Pharmaceuticals, Par Pharmaceutical, and Paddock Laboratories) regarding… [read post]
28 Jun 2010, 8:00 am
The court’s decision dramatically expands the number of investor suits against pharmaceutical companies that state a claim and substantially increases the pressure on companies to settle meritless claims. [read post]
24 Jun 2010, 5:00 am
To the extent that pharmaceutical companies had a practice of disclosing every adverse report on their web site, for example, it is unlikely that analysts would object. [read post]
23 Jun 2010, 5:00 am
In addition, however, it would be both unimportant to investors ("Any reasonably sophisticated investor buying shares in a pharmaceutical company must realize that consumers will, from time to time, experience adverse events after using the company’s product. [read post]
22 Jun 2010, 9:00 am
This case inolves the alleged failure of Matrixx, a pharmaceutical company, to disclose that there was evidence that one of its cold products, Zicam Cold Remedy, caused anosmia, or the loss of smell. [read post]
14 Jun 2010, 6:12 pm
Par Pharmaceutical filed an ANDA to make a time-released version of the opiate tramadol. [read post]
10 Jun 2010, 3:58 am
Par Pharmaceutical, Inc. [read post]
7 Jun 2010, 9:59 pm
Par Pharmaceutical, Inc., the Federal Circuit exercised its prerogative to illustrate its fractured jurisprudence on two issues, obviousness and inequitable conduct, in a (fortunately) nonprecedential decision. [read post]
3 Jun 2010, 2:23 pm
In 2003, pursuant to the Hatch-Waxman Act, two generic companies, Watson Pharmaceuticals and Paddock Laboratories (in partnership with Par Pharmaceuticals), each filed Abbreviated New Drug Applications ("ANDAs") with the FDA, seeking to market much cheaper, generic versions of AndroGel well before the expiration of Solvay's patent in 2020. [read post]
12 May 2010, 5:49 pm
The members of the Creditors' Committee are: Par Pharmaceutical, Inc. [read post]
5 May 2010, 4:46 am
Cyclacel Pharmaceuticals Inc. [read post]
26 Apr 2010, 7:56 am
Par Pharmaceutical, Inc., C.A. [read post]
